PRME
Prime Medicine, Inc.
$3.64
+0.06
(+1.68%)
Mkt Cap
657.45M
Volume
1,832,772
52W Range
2.67-6.94
Sector
Healthcare
Beta
2.31
EPS (TTM)
-1.10 USD
P/E Ratio
-2.57
Revenue (TTM)
4.07M USD
Rev Growth (5Y)
-2.3%
EPS Growth (5Y)
N/A
Company Description
Prime Medicine, Inc. operates as a biotechnology firm, dedicated to delivering genetic therapies for various diseases by strategically employing advanced gene editing technology. Central to their platform is the "Prime Editor" system, which combines a unique Prime Editor protein—a hybrid composed of a Cas protein and a reverse transcriptase enzyme—with a specialized pegRNA molecule. This pegRNA plays a crucial role by both guiding the Prime Editor to a precise location within the genome and providing the essential template for introducing the desired modification to the target DNA sequence. The company, founded in 2019, maintains its headquarters in Cambridge, Massachusetts.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|
| Revenue | 4.63M | 2.98M | 0 | 0 | 0 | 5.21M | 0 |
| Net Income | (201.14M) | (195.88M) | (198.13M) | (121.82M) | (165.37M) | (3.41M) | (2.53M) |
| EPS | -1.35 | -1.65 | -2.18 | -1.46 | -1.92 | -0.05 | -0.03 |
| Free Cash Flow | (167.09M) | (130.16M) | (174.14M) | (147.92M) | (38.23M) | (6.18M) | (1.33M) |
| FCF / Share | -1.12 | -1.10 | -1.91 | -1.52 | -0.40 | -0.06 | -0.01 |
| Operating CF | (162.56M) | (122.86M) | (165.41M) | (131.83M) | (34.08M) | (5.54M) | (1.33M) |
| Total Assets | 342.73M | 297.51M | 193.85M | 360.31M | 301.86M | 54.78M | 8.70M |
| Total Debt | 116.43M | 40.79M | 13.63M | 28.75M | 10.41M | 0 | 0 |
| Cash & Equiv | 63.03M | 182.48M | 41.57M | 187.62M | 185.42M | 36.98M | 8.65M |
| Book Value | 120.87M | 153.15M | 133.07M | 316.27M | 239.56M | 33.47M | 1.39M |
| Return on Equity | -1.66 | -1.28 | -1.49 | -0.39 | -0.69 | -0.10 | -1.82 |
| Metric | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.15M | 856,000 | 838,000 | 1.23M | 1.11M | 1.45M | 2.18M | 209,000 | 0 | 591,000 | 0 | 0 |
| Net Income | (42.11M) | (49.12M) | (46.08M) | (50.58M) | (52.59M) | (51.89M) | (42.28M) | (52.52M) | (55.33M) | (45.76M) | (65.64M) | (50.71M) |
| EPS | -0.24 | -0.28 | -0.26 | -0.32 | -0.41 | -0.40 | -0.36 | -0.44 | -0.46 | -0.44 | -0.67 | -0.55 |
| Free Cash Flow | (41.09M) | (42.92M) | (37.55M) | (35.29M) | (42.98M) | (51.28M) | 14.45M | (27.19M) | (47.39M) | (70.03M) | (45.70M) | (42.08M) |
| FCF / Share | -0.23 | -0.24 | -0.25 | -0.22 | -0.33 | -0.39 | 0.12 | -0.23 | -0.40 | -0.67 | -0.47 | -0.46 |
| Operating CF | (41.05M) | (42.71M) | (37.26M) | (35.04M) | (41.41M) | (48.86M) | 16.25M | (25.91M) | (45.49M) | (67.71M) | (43.86M) | (39.17M) |
| Total Assets | 249.04M | 294.73M | 342.73M | 385.01M | 279.01M | 328.16M | 297.51M | 332.78M | 259.70M | 311.38M | 193.85M | 239.15M |
| Total Debt | 112.48M | 114.51M | 116.43M | 118.14M | 119.74M | 121.15M | 40.79M | 41.25M | 41.58M | 43.79M | 13.63M | 17.04M |
| Cash & Equiv | 47.45M | 64.11M | 63.03M | 71.40M | 53.80M | 91.88M | 182.48M | 117.98M | 55.60M | 94.16M | 41.57M | 43.96M |
| Book Value | 39.81M | 76.70M | 120.87M | 161.82M | 60.86M | 106.92M | 153.15M | 189.50M | 196.59M | 243.77M | 133.07M | 193.96M |
| Return on Equity | -1.06 | -0.64 | -0.38 | -0.31 | -0.86 | -0.49 | -0.28 | -0.28 | -0.28 | -0.19 | -0.49 | -0.26 |
PRME News
Prime Medicine: Soon In The Clinic
Prime Medicine, Inc. (PRME) Reports Q2 Loss, Misses Revenue Estimates
Prime Medicine, Inc. (PRME) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
Prime Medicine Announces U.S. FDA Clearance of Investigational New Drug Application for PM577a in H1069Q-mutated Wilson Disease
Prime Medicine, Inc. $PRME Shares Sold by Amova Asset Management Americas Inc.
Prime Medicine Beats Beam Therapeutics In Patent Dispute - But Both Are Investable
Prime Medicine Secures Favorable Arbitration Ruling in Beam Therapeutics Case
Prime Medicine Announces Positive Resolution to Arbitration with Beam Therapeutics
Prime Medicine Receives U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for PM359 for the Treatment of Chronic Granulomatous Disease (CGD)
Prime Medicine Announces New Zealand Clearance of Clinical Trial Application for PM577a in H1069Q-mutated Wilson Disease